Fibrates: Modes of Action

[1]  T. Kristensen,et al.  Plasma fibrinogen and ischemic heart disease risk factors. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[2]  C. Packard,et al.  Postprandial lipemia, fenofibrate and coronary artery disease. , 1990, Atherosclerosis.

[3]  J. Breslow,et al.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. , 1990, Science.

[4]  R. Havel.  Role of triglyceride-rich lipoproteins in progression of atherosclerosis. , 1990, Circulation.

[5]  G. Utermann,et al.  The mysteries of lipoprotein(a). , 1989, Science.

[6]  E. Bosisio,et al.  Effect of bezafibrate on plasma lipid in a strain of genetically hypercholesterolemic RICO rats. , 1989, Pharmacological research.

[7]  J. Witztum,et al.  Current approaches to drug therapy for the hypercholesterolemic patient. , 1989, Circulation.

[8]  E. Fisher,et al.  Effects of eicosapentaenoic and docosahexaenoic acids on apoprotein B mRNA and secretion of very low density lipoprotein in HepG2 cells. , 1989, Arteriosclerosis.

[9]  K. Einarsson,et al.  Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes. , 1989, Journal of lipid research.

[10]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[11]  M. Hayden,et al.  Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial. , 1988, Atherosclerosis.

[12]  C. Packard,et al.  Influence of etofibrate on low density lipoprotein metabolism. , 1988, Atherosclerosis.

[13]  G. Franceschini,et al.  Effects of fibrates on serum lipids and atherosclerosis. , 1988, Pharmacology & therapeutics.

[14]  R. Palmer.  Effects of fibric acid derivatives on biliary lipid composition. , 1987, The American journal of medicine.

[15]  A. Sorisky,et al.  Change in composition of high density lipoprotein during gemfibrozil therapy. , 1987, Atherosclerosis.

[16]  P. Moulin,et al.  High density lipoprotein alterations induced by bezafibrate in healthy male volunteers. , 1987, Atherosclerosis.

[17]  G. Schonfeld,et al.  Hypolipidemic therapy modulates expression of apolipoprotein B epitopes on low density lipoproteins. Studies in mild to moderate hypertriglyceridemic patients. , 1987, Journal of lipid research.

[18]  M. Weintraub,et al.  Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. , 1987, The Journal of clinical investigation.

[19]  K. von Bergmann,et al.  Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. , 1988, Journal of lipid research.

[20]  T. Kjellström,et al.  The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. , 1986, Atherosclerosis.

[21]  S. Eisenberg,et al.  Change in very low‐, low‐, and high‐density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia , 1986, European journal of clinical investigation.

[22]  S. Eisenberg,et al.  Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy. , 1985, The Journal of clinical investigation.

[23]  R. Havel,et al.  Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. , 1985, Journal of lipid research.

[24]  P. Gartside,et al.  Mechanism of action of gemfibrozil on lipoprotein metabolism. , 1985, The Journal of clinical investigation.

[25]  B. Chanu,et al.  Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. , 1985, Atherosclerosis.

[26]  J. Vollmar,et al.  Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers. , 1985, Pharmatherapeutica.

[27]  G. Franceschini,et al.  Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. , 1985, Artery.

[28]  A. Gotto,et al.  Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. , 1984, The Journal of clinical investigation.

[29]  R. Boston,et al.  Suppression by diets rich in fish oil of very low density lipoprotein production in man. , 1984, The Journal of clinical investigation.

[30]  S. Grundy,et al.  Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man , 1984 .

[31]  C. Packard,et al.  Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. , 1982, Atherosclerosis.

[32]  H. Lithell,et al.  Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate. , 1982, Atherosclerosis.

[33]  Uno Erikson,et al.  REGRESSION OF COMPUTER ESTIMATED FEMORAL ATHEROSCLEROSIS AFTER PRONOUNCED SERUM LIPID LOWERING IN PATIENTS WITH ASYMPTOMATIC HYPERLIPIDAEMIA , 1982, The Lancet.

[34]  C. Ehnholm,et al.  Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. , 2009, Acta medica Scandinavica.

[35]  S. Grundy,et al.  Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia. , 1981, Metabolism: clinical and experimental.

[36]  M. Wahlqvist,et al.  Clofibrate raises plasma apoprotein A-I and HDL-cholesterol concentrations. , 1980, Atherosclerosis.

[37]  Ann-Margret Östlund-Lindqvist,et al.  Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters. , 1980, Atherosclerosis.

[38]  M. Kohlmeier,et al.  Biliary and plasma lipids and lipid-lowering chemotherapy Studies with clofibrate, fenofibrate and etofibrate in healthy volunteers , 1980 .

[39]  S. Thompson,et al.  HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDY , 1980, The Lancet.

[40]  E. Bosisio,et al.  Effect of bezafibrate on liver enzymes and lipoproteins in animal experiments. , 1980 .

[41]  P. Schwandt,et al.  Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV. , 1980, Artery.

[42]  A. Goldberg,et al.  Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. , 1979, The New England journal of medicine.

[43]  D. B. Zilversmit.  Atherogenesis: a postprandial phenomenon. , 1979, Circulation.

[44]  J. Berndt,et al.  Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver. , 1978, Atherosclerosis.

[45]  H. Lithell,et al.  Increase of the lipoprotein‐lipase activity in human skeletal muscle during clof ibrate administration , 1978, European journal of clinical investigation.

[46]  A. Gotto,et al.  Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia. , 1977, The American journal of medicine.

[47]  H. Greten,et al.  Comparison of assay methods for selective measurement of plasma lipase. The effect of clofibrate on hepatic and lipoprotein lipase in normals and patients with hypertriglyceridemia. , 1977, Atherosclerosis.

[48]  D. Ballantyne,et al.  On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemias in type IV and type V hyperlipoproteinaemias. , 1977, Atherosclerosis.

[49]  M. Laimins,et al.  Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with an without vascular disease. , 1977, Metabolism: clinical and experimental.

[50]  D. B. Zilversmit,et al.  Chylomicron remnant cholesteryl esters as the major constituent of very low density lipoproteins in plasma of cholesterol-fed rabbits. , 1977, Journal of lipid research.

[51]  J. Huttunen,et al.  Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. , 1977, Metabolism: clinical and experimental.

[52]  A. Kissebah,et al.  Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia: effects of 2,2-dimethyl, 5(2, 5-xylyoxy) valeric acid therapy. , 1976, Atherosclerosis.

[53]  Carlson La.  Effect of gemfibrozil in vitro on fat-mobilizing lipolysis in human adipose tissue. , 1976 .

[54]  J. Dormandy,et al.  Effect of Clofibrate on Blood Viscosity in Intermittent Claudication , 1974, British medical journal.

[55]  S. Shefer,et al.  Effects of clofibrate on sterol metabolism in the rat. , 1974, Biochimica et biophysica acta.

[56]  Maddocks Ac.  Letter: Sterilisation of cardiac bioptome. , 1974 .

[57]  A. Kissebah,et al.  The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) on the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV und Type V Hypertriglyceridaemia , 1974, European journal of clinical investigation.

[58]  J. Wasvary,et al.  On the mode of action of lipid-lowering agents. VII. In vivo inhibition and reversible binding of hepatic acetyl coenzyme A carboxylase by hypolipidemic drugs. , 1972, The Journal of biological chemistry.

[59]  H. Hankin,et al.  On the mode of action of lipid-lowering agents. V. Kinetics of the inhibition in vitro of rat acetyl coenzyme A carboxylase. , 1971, The Journal of biological chemistry.

[60]  D. Porte,et al.  On the mechanism of action of atromid-S on triglyceride transport in man. , 1970, Transactions of the Association of American Physicians.